Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Bullboard Posts
Post by santi69on Oct 16, 2015 7:40am
170 Views
Post# 24196937

NEWS! Rollback up to 100 shares for 1 share

NEWS! Rollback up to 100 shares for 1 share

Aeterna Zentaris Announces Special Meeting of Shareholders and Mailing of Management Information Circular


QUEBEC CITY, Oct. 16, 2015 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Corporation") today announced that it has convened a special meeting of shareholders (the "Meeting") to be held on Monday, November 16, 2015, at 9:30 a.m. (Eastern time) for shareholders of record on October 14, 2015 to consider a special resolution authorizing the consolidation of the issued and outstanding common shares of the Corporation at a consolidation ratio of between 8-for-1 and 100-for-1 (the "Share Consolidation") and that the Notice of Special Meeting of Shareholders and Management Information Circular (the "Circular") have been mailed to shareholders.

David Dodd, Chairman and CEO of Aeterna Zentaris, commented, "We are asking our shareholders to approve a share consolidation of up to 100-for-1 in order to avoid a potential delisting of our Common Shares from The NASDAQ Capital Market and to improve our capital structure. We believe that the consolidation could heighten the interest of the financial community in us and potentially broaden the pool of investors that may consider investing or be able to invest in us by increasing the trading price of our Common Shares. It could also help to attract institutional investors who have internal policies that either prohibit them from purchasing stocks below a certain minimum price or tend to discourage individual brokers from recommending such stocks to their customers."

As of the record date for the Meeting of October 14, 2015, there were 544,179,214 issued and outstanding Common Shares and approximately 5.3 million issued and outstanding Series B Share Purchase Warrants, representing approximately 17.7% of the number originally issued.

The Circular contains, among other things, details concerning the Share Consolidation, reasons that the Corporation's Board of Directors recommends the Share Consolidation, requirements for the Share Consolidation to be implemented and the procedure for receiving new shares if the Share Consolidation is implemented, as well as the procedures for voting at the meeting and other related matters. Shareholders are urged to carefully review the Circular and accompanying materials as they contain important information regarding the Share Consolidation and its consequences to Shareholders. A copy of the Circular is available on SEDAR at www.sedar.com and on the EDGAR section of the U.S. Securities and Exchange Commission's website at www.sec.gov.

The Board of Directors UNANIMOUSLY recommends that Shareholders vote FOR the Share Consolidation.

Click here for news

Bullboard Posts